$366 Million is the total value of Darwin Global Management, Ltd.'s 4 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TGTX | New | TG THERAPEUTICS INC | $157,186,665 | – | 10,451,241 | +100.0% | 42.99% | – |
ARGX | Sell | ARGENX SEsponsored adr | $106,259,071 | -5.8% | 285,198 | -4.2% | 29.06% | -58.6% |
AMAM | Buy | AMBRX BIOPHARMA INCsponsored ads | $100,836,791 | +485.7% | 11,304,573 | +49.0% | 27.58% | +157.3% |
KROS | Sell | KEROS THERAPEUTICS INC | $1,340,182 | -93.5% | 31,386 | -92.7% | 0.37% | -97.1% |
RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -91,379 | -100.0% | -6.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
INHIBRX INC | 5 | Q4 2021 | 3.9% |
ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
ARGENX SE | 4 | Q3 2023 | 70.2% |
BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
4 | 2023-06-28 |
SC 13D/A | 2023-06-28 |
SC 13D/A | 2023-05-25 |
13F-HR | 2023-05-15 |
SC 13G | 2023-04-03 |
3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.